###begin article-title 0
MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis
###end article-title 0
###begin article-title 1
A Blood Test for Lung Fibrosis?
###end article-title 1
###begin title 2
Background
###end title 2
###begin p 3
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease associated with substantial morbidity and mortality. The objective of this study was to determine whether there is a peripheral blood protein signature in IPF and whether components of this signature may serve as biomarkers for disease presence and progression.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 1380 1382 1380 1382 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CO</sub>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
###xml 579 587 <span type="species:ncbi:9606">patients</span>
###xml 924 932 <span type="species:ncbi:9606">patients</span>
###xml 1116 1124 <span type="species:ncbi:9606">patients</span>
###xml 1212 1220 <span type="species:ncbi:9606">patients</span>
We analyzed the concentrations of 49 proteins in the plasma of 74 patients with IPF and in the plasma of 53 control individuals. We identified a combinatorial signature of five proteins-MMP7, MMP1, MMP8, IGFBP1, and TNFRSF1A-that was sufficient to distinguish patients from controls with a sensitivity of 98.6% (95% confidence interval [CI] 92.7%-100%) and specificity of 98.1% (95% CI 89.9%-100%). Increases in MMP1 and MMP7 were also observed in lung tissue and bronchoalveolar lavage fluid obtained from IPF patients. MMP7 and MMP1 plasma concentrations were not increased in patients with chronic obstructive pulmonary disease or sarcoidosis and distinguished IPF compared to subacute/chronic hypersensitivity pneumonitis, a disease that may mimic IPF, with a sensitivity of 96.3% (95% CI 81.0%-100%) and specificity of 87.2% (95% CI 72.6%-95.7%). We verified our results in an independent validation cohort composed of patients with IPF, familial pulmonary fibrosis, subclinical interstitial lung disease (ILD), as well as with control individuals. MMP7 and MMP1 concentrations were significantly higher in IPF patients compared to controls in this cohort. Furthermore, MMP7 concentrations were elevated in patients with subclinical ILD and negatively correlated with percent predicted forced vital capacity (FVC%) and percent predicted carbon monoxide diffusing capacity (DLCO%).
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
Our experiments provide the first evidence for a peripheral blood protein signature in IPF to our knowledge. The two main components of this signature, MMP7 and MMP1, are overexpressed in the lung microenvironment and distinguish IPF from other chronic lung diseases. Additionally, increased MMP7 concentration may be indicative of asymptomatic ILD and reflect disease progression.
###end p 7
###begin p 8
Naftali Kaminski and colleagues find increased levels of specific proteins in the bloodstream of individuals with idiopathic pulmonary fibrosis, and suggest that these proteins may ultimately provide a biomarker for the disease.
###end p 8
###begin title 9
Editors' Summary
###end title 9
###begin title 10
Background.
###end title 10
###begin p 11
###xml 150 156 <span type="species:ncbi:9606">people</span>
###xml 1084 1090 <span type="species:ncbi:9606">people</span>
Idiopathic pulmonary fibrosis (IPF) is a serious disease in which the lungs become progressively scarred or thickened for unknown reasons. In healthy people, air is taken in through the mouth or nose and travels down the windpipe into tubes in the lungs called the airways. Each airway has many small branches that end in alveoli, tiny air sacs with thin walls that are surrounded by small blood vessels called capillaries. When air reaches the alveoli, the oxygen in it passes into the bloodstream and is taken to the organs of the body to keep them working. In IPF, the alveoli and the space around them (the "interstitial" area) gradually become scarred and thickened, which stops oxygen's movement into the bloodstream. When only small areas of the lung are scarred, IPF may cause no symptoms. But, as more of the lung becomes damaged, IPF eventually causes breathlessness, even when resting. There is no effective treatment for IPF, although steroids and drugs that suppress the body's immune system are often tried in an attempt to slow its progression. On average, half of the people with IPF die within three years of diagnosis, often from respiratory or heart failure.
###end p 11
###begin title 12
Why Was This Study Done?
###end title 12
###begin p 13
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 458 466 <span type="species:ncbi:9606">patients</span>
###xml 734 741 <span type="species:ncbi:9606">patient</span>
It can be difficult to diagnose IPF-there are many lung diseases with similar symptoms, including numerous other interstitial lung diseases-and currently, physicians can only follow the progression of IPF by repeatedly testing their patients' lung function or by doing multiple chest X-rays. If proteins could be identified whose level in blood indicated disease activity (so-called "peripheral blood biomarkers"), it would be easier to diagnose and monitor patients. In addition, the identification of such biomarkers might suggest new drug targets for the treatment of IPF. In this study, the researchers look for peripheral blood biomarkers in IPF by using a "multiplex analysis" system to measure the level of several proteins in patient blood samples simultaneously.
###end p 13
###begin title 14
What Did the Researchers Do and Find?
###end title 14
###begin p 15
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 133 139 <span type="species:ncbi:9606">people</span>
###xml 258 266 <span type="species:ncbi:9606">patients</span>
###xml 289 301 <span type="species:ncbi:9606">participants</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
###xml 659 667 <span type="species:ncbi:9606">patients</span>
###xml 801 809 <span type="species:ncbi:9606">patients</span>
###xml 827 835 <span type="species:ncbi:9606">patients</span>
###xml 938 946 <span type="species:ncbi:9606">patients</span>
###xml 1067 1075 <span type="species:ncbi:9606">patients</span>
###xml 1289 1295 <span type="species:ncbi:9606">people</span>
The researchers measured the levels of 49 plasma proteins (plasma is the fluid part of blood) in 74 patients with IPF and 53 healthy people (controls) and used a technique called "recursive partitioning" to define a five-protein signature that distinguished patients from unaffected study participants (controls). Matrix metalloproteinase 7 (MMP7) and MMP1-the two plasma proteins whose levels were most increased in patients with IPF compared to controls-were key components of this signature. Concentrations of MMP7 and MMP1 were higher in bronchoalveolar lavage samples (fluid obtained by washing out the lungs with saline) and in lung tissue samples from patients with IPF than in similar samples taken from healthy individuals. Plasma concentrations of MMP7 and MMP1 were significantly higher in patients with IPF than in patients with hypersensitivity pneumonitis, an interstitial lung disease that mimics IPF, but not increased in patients with chronic obstructive pulmonary disease or sarcoidosis, two other lung diseases. In an independent validation group, patients with IPF and familial pulmonary fibrosis had increased plasma concentrations of MMP7 and MMP1 that correlated with the severity of their disease. In addition, MMP7 concentrations were raised in close relatives of people with familial pulmonary fibrosis who had normal lung function tests but some lung scarring.
###end p 15
###begin title 16
What Do These Findings Mean?
###end title 16
###begin p 17
These findings provide evidence for a protein signature in the blood for IPF and suggest MMP1 and MMP7 may be useful as biomarkers for IPF. These two matrix metalloproteinases have previously been suggested to be involved in the development of IPF. However, additional work is probably needed to confirm that increased plasma concentrations MMP7 and MMP1 are specific for IPF, since it may be that these markers will not distinguish IPF from other interstitial lung diseases.
###end p 17
###begin title 18
Additional Information.
###end title 18
###begin p 19
Please access these Web sites via the online version of this summary at .
###end p 19
###begin p 20
###xml 15 28 15 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLoS Medicine</italic>
Read a related PLoS Medicine article
###end p 20
###begin p 21
The MedlinePlus Encyclopedia has a page on  (in English and Spanish) and on
###end p 21
###begin p 22
###xml 50 58 <span type="species:ncbi:9606">patients</span>
The  and the  also provide information on IPF for patients and relatives
###end p 22
###begin p 23
Some of the researchers involved in this study provide more details about what might go wrong in IPF in a recent
###end p 23
###begin title 24
Introduction
###end title 24
###begin p 25
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b001">1</xref>
###xml 608 609 608 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b002">2</xref>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b004">4</xref>
###xml 481 489 <span type="species:ncbi:9606">patients</span>
Idiopathic pulmonary fibrosis (IPF), a progressive fibrotic interstitial lung disease (ILD) with median survival of 2.5-3 y, is largely unaffected by currently available medical therapies [1]. The disease is characterized by alveolar epithelial cell injury and activation, fibroblast/myofibroblast foci formation, and exaggerated accumulation of extracellular matrix in the lung parenchyma. Recent studies employing high-throughput genomic technologies to analyze samples from IPF patients or genetically modified animals have highlighted the complexity of the pathways involved in the disease (reviewed in [2-4]). While these studies have improved the understanding of the molecular mechanisms underlying lung fibrosis, they did not translate well into the clinical arena.
###end p 25
###begin p 26
###xml 671 672 671 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b005">5</xref>
###xml 681 682 681 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b006">6</xref>
###xml 691 692 691 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b007">7</xref>
###xml 702 703 702 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b008">8</xref>
###xml 723 724 719 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b009">9</xref>
###xml 751 753 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b010">10</xref>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 352 360 <span type="species:ncbi:9606">Patients</span>
###xml 777 785 <span type="species:ncbi:9606">patients</span>
Identification of peripheral blood biomarkers may facilitate the diagnosis and follow-up of patients with IPF as well as the implementation of new therapeutic interventions. Currently, establishing a diagnosis of IPF may require surgical lung biopsy in patients with atypical clinical presentations or high-resolution computed tomography (HRCT) scans. Patients with IPF are often evaluated by serial pulmonary physiology measurements and repeated radiographic examinations. These studies provide a general assessment of the extent of disease, but do not provide information about disease activity on a molecular level. Higher serum concentrations of surfactant proteins [5], KL-6 [6], FASL [7], CCL-2 [8], alpha-defensins [9], and most recently SPP1 [10] have been reported in patients with IPF and other ILDs, but most of these studies were modest in size and assayed only a single or a few protein markers simultaneously.
###end p 26
###begin p 27
###xml 284 292 <span type="species:ncbi:9606">patients</span>
###xml 529 537 <span type="species:ncbi:9606">patients</span>
In this study, we used a multianalyte protein assay system to simultaneously measure concentrations of 49 plasma proteins, including cytokines, chemokines, growth and angiogenic factors, matrix metalloproteases (MMPs), and markers of apoptosis in a derivation cohort comprised of IPF patients and healthy controls. We identified a combinatorial signature of five proteins; of these, we measured concentrations of two metalloproteases, MMP7 and MMP1, in other chronic lung diseases and compared them to the levels observed in IPF patients. Finally, the potential role of MMP7 and MMP1 as IPF peripheral blood biomarkers was tested in an independent validation cohort.
###end p 27
###begin title 28
Methods
###end title 28
###begin p 29
###xml 64 71 64 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050093-sd006">Text S1</xref>
For detailed description of the methods used in this study, see Text S1.
###end p 29
###begin title 30
Initial IPF Derivation Cohort
###end title 30
###begin p 31
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b011">11</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b012">12</xref>
###xml 238 245 238 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050093-sd006">Text S1</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b013">13</xref>
###xml 517 524 517 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050093-t001">Table 1</xref>
###xml 678 680 676 678 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CO</sub>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 589 597 <span type="species:ncbi:9606">patients</span>
This study included 74 patients with IPF evaluated at the University of Pittsburgh Medical Center. The diagnosis of IPF was established on the basis of published criteria [11], and surgical lung biopsy when clinically indicated [12] (see Text S1). Clinical data were available through the Simmons Center database. Smoking status was defined as previously described [13]. Fifty-three control individuals were obtained from the pulmonary division sample collection core. Baseline demographic information is detailed in Table 1. The mean percent predicted forced vital capacity (FVC%) of IPF patients was 61.9 +/- 20.8; mean percent predicted carbon monoxide diffusing capacity (DLCO%) was 42.1 +/- 17.4.
###end p 31
###begin p 32
###xml 18 25 <span type="species:ncbi:9606">Patient</span>
Derivation Cohort Patient Characteristics
###end p 32
###begin title 33
Chronic Obstructive Pulmonary Disease
###end title 33
###begin p 34
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b014">14</xref>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 222 229 <span type="species:ncbi:4097">tobacco</span>
###xml 485 493 <span type="species:ncbi:9606">patients</span>
###xml 518 526 <span type="species:ncbi:9606">patients</span>
###xml 548 556 <span type="species:ncbi:9606">patients</span>
Plasma samples from 73 patients with chronic obstructive pulmonary disease (COPD) evaluated at the University of Pittsburgh were available for this study. Individuals were clinically stable at the time of examination, had tobacco exposure of at least ten pack years, and had no clinical diagnosis of rheumatologic, infectious, or other systemic inflammatory disease. Disease severity was measured using the GOLD classification as previously described [14]. The COPD cohort included 13 patients with GOLD class 0-I, 21 patients with GOLD II, and 39 patients with GOLD III-IV.
###end p 34
###begin title 35
Sarcoidosis
###end title 35
###begin p 36
###xml 147 148 147 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 216 218 214 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CO</sub>
###xml 397 399 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b015">15</xref>
###xml 400 402 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b016">16</xref>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 119 127 <span type="species:ncbi:9606">Patients</span>
Plasma samples from 47 patients with sarcoidosis evaluated at the University of Pittsburgh Medical Center were tested. Patients with lung disease (n = 29) demonstrated an average FVC% of 76.7 +/- 22.1, and average DLCO% of 72.9 +/- 25.5. The diagnosis and staging of disease was determined according to American Thoracic Society and European Respiratory Society criteria, as previously described [15,16].
###end p 36
###begin title 37
Hypersensitivity Pneumonitis
###end title 37
###begin p 38
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b017">17</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b018">18</xref>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 306 314 <span type="species:ncbi:9606">patients</span>
###xml 729 737 <span type="species:ncbi:9606">patients</span>
###xml 903 911 <span type="species:ncbi:9606">patients</span>
Serum samples from 41 patients with subacute/chronic hypersensitivity pneumonitis (HP) and 34 patients with IPF evaluated at Instituto Nacional de Enfermedades Respiratorias in Mexico were available for this study. Diagnosis of IPF and HP has been previously described for this cohort [17,18]. Briefly, HP patients showed the following features: (a) antecedent bird exposure and positive serum antibodies against avian antigens; (b) clinical and functional features of ILD; (c) HRCT showing diffuse centrilobular poorly defined micronodules, ground glass attenuation, focal air trapping, and mild to moderate fibrotic changes; and (d) greater than 35% lymphocytes in bronchoalveolar lavage (BAL) fluid. Forty-four percent of the patients had a surgical lung biopsy; in all cases lung histology was consistent with the diagnosis of HP. The average FVC% was 60.3 +/- 15.3 for HP and 59.1 +/- 17.2 for IPF patients.
###end p 38
###begin title 39
Independent Validation Cohort
###end title 39
###begin p 40
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b019">19</xref>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 295 303 <span type="species:ncbi:9606">Patients</span>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
Serum samples from 20 control individuals, eight patients with subclinical idiopathic ILD, 16 patients with familial pulmonary fibrosis, and nine with sporadic IPF, evaluated at the Warren Grant Magnuson Clinical Center of the National Institutes of Health (NIH), were available for this study. Patients with subclinical disease were first-degree relatives of patients with familial pulmonary fibrosis; they were asymptomatic, with normal pulmonary function tests but HRCT findings consistent with early ILD. Familial pulmonary fibrosis was defined as previously described [19]. Normal volunteers were used as controls.
###end p 40
###begin p 41
###xml 52 54 52 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b020">20</xref>
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b021">21</xref>
###xml 308 310 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b021">21</xref>
###xml 440 447 434 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050093-t002">Table 2</xref>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
These cohorts have been previously described by us [20,21]. Briefly, the mean FVC% values for patients with sporadic IPF and familial pulmonary fibrosis were 59.4 +/- 19.7 and 75.7 +/- 16.7, respectively. Eight patients with familial pulmonary fibrosis were diagnosed with early asymptomatic ILD using HRCT [21]; the mean FVC% in this group was 101.3 +/- 10.1. Gender, age, ethnic origin, and smoking status for all groups are presented in Table 2.
###end p 41
###begin p 42
###xml 18 25 <span type="species:ncbi:9606">Patient</span>
Validation Cohort Patient Characteristics
###end p 42
###begin p 43
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b022">22</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b012">12</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b023">23</xref>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b011">11</xref>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 568 576 <span type="species:ncbi:9606">patients</span>
Lung tissue samples for microarray analysis were obtained through the University of Pittsburgh Health Sciences Tissue Bank as we previously described [22]. Twenty-three samples were obtained from surgical remnants of biopsies or lungs explanted from patients with IPF who underwent pulmonary transplant and 14 control normal lung tissues obtained from the disease free margins with normal histology of lung cancer resection specimens. The morphologic diagnosis of IPF was based on typical microscopic findings consistent with usual interstitial pneumonia [12,23]. All patients fulfilled the diagnostic criteria for IPF outlined by the American Thoracic Society and European Respiratory Society [11].
###end p 43
###begin p 44
###xml 238 246 <span type="species:ncbi:9606">patients</span>
All studies were approved by the Institutional Review Board at the University of Pittsburgh, the National Heart, Lung, and Blood Institute, or the National Institute of Respiratory Diseases, Mexico. Informed consent was obtained from all patients.
###end p 44
###begin title 45
Blood Samples
###end title 45
###begin p 46
###xml 29 41 <span type="species:ncbi:9606">participants</span>
Blood (45 ml) was drawn from participants using standardized phlebotomy procedures. Plasma or serum was separated by centrifugation, and all specimens were immediately aliquoted and frozen.
###end p 46
###begin title 47
BAL
###end title 47
###begin p 48
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b018">18</xref>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b022">22</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b024">24</xref>
###xml 207 215 <span type="species:ncbi:9606">patients</span>
BAL was performed through flexible fiberoptic bronchoscopy as part of the diagnostic process, as we previously described [18,22,24]. Supernatants were kept at -70 degreesC until use. BAL samples from 22 IPF patients (age 62.2 +/- 7.2 y) and ten normal controls (age 41.5 +/- 5 y) were available for this study.
###end p 48
###begin title 49
Multiplex Analysis
###end title 49
###begin p 50
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b025">25</xref>
###xml 219 226 219 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050093-sd006">Text S1</xref>
Assays were performed using Luminex xMAP technology (Luminex Corporation) in 96-well microplate format according to appropriate manufacturers' protocols (Invitrogen and R&D Systems), as previously described [25] and in Text S1.
###end p 50
###begin title 51
Bead-Based Immunoassays
###end title 51
###begin p 52
A 34-plex assay was performed for IL1A, IL1RA, IL1B, IL2, IL2R, IL4, IL5, IL6, IL7, IL8, IL10, IL12B, IL13, IL15, IL17, TNFA, IFNA, IFNG, GMCSF, EGF, VEGF, GCSF, FGF2, HGF, CXCL9, CXCL10, CCL2, CCL3, CCL4, CCL5, CCL11, TNFRS1A, TNFRS1B, and TRAIL-R2 (Invitrogen). MMP assays included MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP12, and MMP13 (R&D Systems).
###end p 52
###begin p 53
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b025">25</xref>
Assays for FAS, EGFR, FASL, Cyfra 21-1 (CKRT19 fragment), IGFBP1, and KLK10 were developed in our Pittsburgh Luminex Core Facility. The assays were validated as described [25].
###end p 53
###begin title 54
ELISA
###end title 54
###begin p 55
###xml 45 50 <span type="species:ncbi:9606">human</span>
Quantitative sandwich enzyme immunoassay for human MMP1, MMP7, and AGER was performed as recommended by the manufacturer (R&D Systems).
###end p 55
###begin title 56
Oligonucleotide Microarray Experiments
###end title 56
###begin p 57
###xml 36 43 36 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050093-sd006">Text S1</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b026">26</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b027">27</xref>
###xml 292 297 <span type="species:ncbi:9606">Human</span>
Detailed information is provided in Text S1. Briefly, total RNA was used as a template for synthesis of cDNA as recommended by the manufacturer of the arrays (Agilent Technologies). The cDNA was used as a template to generate Cy3-labeled cRNA that was used for hybridization on Agilent Whole Human Genome 4X 44K multipack arrays (Agilent Technologies). After hybridization, scanning, and feature extraction, data files were imported into a microarray database and linked with updated gene annotations using SOURCE () and then normalized using cyclic LOESS [26]. Differentially expressed genes were identified using significant analysis of microarrays (SAM) [27]. Probes corresponding to the 49 protein markers were identified through their gene symbols. Expression levels for the probes that corresponded to these markers were extracted. In the case of redundant probes, those with the highest expression level and with the lowest Q-value were selected for presentation.
###end p 57
###begin title 58
Statistical Analysis
###end title 58
###begin p 59
###xml 139 140 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 523 525 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b028">28</xref>
###xml 906 908 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b027">27</xref>
###xml 979 981 977 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b029">29</xref>
A protein was considered differentially expressed when there was a change of at least 25% in concentration and statistical significance at p < 0.05 corrected for multiple testing. Data are reported as mean +/- standard deviation. The Wilcoxon rank-sum test was used to identify potential biomarkers that univariately distinguish IPF samples from controls. For multiple testing the Bonferroni method was used to control the family-wise error rate at 5%. Data were analyzed using the R language for statistical computing () [28]. Classification and regression trees (CART) methodology was used to identify potential combinations of peripheral blood biomarkers that could be used to distinguish IPF from controls. CART was performed using the rpart package for recursive partitioning. Classification performance was assessed using the ROCR package (). For oligonucleotide array data analysis, we applied SAM [27]. Data visualization and clustering were performed using Genomica () [29] and Spotfire Decision Site 9 (TIBCO).
###end p 59
###begin title 60
Results
###end title 60
###begin title 61
###xml 32 40 <span type="species:ncbi:9606">Patients</span>
Plasma Proteins Distinguish IPF Patients from Controls in Derivation Cohort
###end title 61
###begin p 62
###xml 53 61 53 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g001">Figure 1</xref>
###xml 171 178 171 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050093-t003">Table 3</xref>
###xml 577 584 577 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050093-t003">Table 3</xref>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
Of 49 markers analyzed, 48 are detectable in plasma (Figure 1A); univariate analysis identified 12 proteins that are differentially expressed in IPF compared to controls (Table 3). Five MMPs (MMP7, MMP1, MMP3, MMP8, MMP9), two chemokines (CXCL10, CCL11), FAS, IL12B, and the soluble TNF receptors (TNFRSF1A, TNFRSF1B) are significantly overexpressed; AGER is significantly underexpressed in plasma of patients with IPF compared to controls. MMP7 and MMP1, which have previously been shown to play a role in IPF pathogenesis, are the top-ranked proteins in univariate analysis (Table 3). Significant differences persist when age, gender, or smoking status is statistically controlled.
###end p 62
###begin title 63
###xml 42 50 <span type="species:ncbi:9606">Patients</span>
Peripheral Blood Proteins Distinguish IPF Patients from Controls
###end title 63
###begin p 64
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
(A) Heatmap of proteins measured in the plasma of IPF and control patients. Columns, individual patients; rows, proteins. Every protein level was divided by the geometric mean of values for the same proteins for all patients and log based 2 transformed. Increasing shades of yellow, increased; increased shades of purple, decreased; gray, unchanged. Proteins were clustered using Genomica. Red vertical line, cluster of proteins increased in IPF; green vertical line, cluster of proteins decreased in IPF.
###end p 64
###begin p 65
###xml 95 103 <span type="species:ncbi:9606">patients</span>
(B) Classification tree obtained by CART applied to plasma protein concentration data from IPF patients and controls. A blue box identifies a terminal node as control; a red box as IPF. All counts are listed as control/IPF. Concentrations are in ng/ml. In the subgroup with high MMP7 concentration but low MMP1 concentration (14 IPF samples, five control samples), splitting on IGFBP1 and TNFRSF1A improves classification, while in the subgroup with low MMP7, MMP8 improves classification.
###end p 65
###begin p 66
###xml 162 163 162 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 311 312 311 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
(C) ROC curves for using each of five markers, or their combination, to classify samples as IPF or control. Sensitivity, or true positive rate, is plotted on the y-axis, and false positive rate, or 1 - specificity, on the x-axis. The area under each ROC curve is equivalent to the numerator of the Mann-Whitney U-statistic comparing the marker distributions between IPF and control samples. The magenta line labeled "Combined" is for the combinatorial classifier using all five markers. The identity line at 45 degrees represents a marker that performed no better than classifying samples as IPF or control by flipping a fair coin.
###end p 66
###begin p 67
Plasma Proteins That Distinguish IPF from Controls
###end p 67
###begin p 68
###xml 447 455 447 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g001">Figure 1</xref>
###xml 1074 1082 1068 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g001">Figure 1</xref>
###xml 1205 1213 1199 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g001">Figure 1</xref>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
###xml 684 692 <span type="species:ncbi:9606">patients</span>
###xml 1001 1009 <span type="species:ncbi:9606">patients</span>
To determine whether combinations of these plasma proteins correctly classify IPF patients, we applied recursive partitioning to the entire set of 49 markers and found that plasma protein profiles clearly distinguish IPF patients from normal controls. CART analysis showed that MMP7 and MMP1, in addition to being the two most significant biomarkers, are key components of a combinatorial classifier that also includes MMP8, IGFBP-1, and TNFRS1A (Figure 1B). Sensitivity and specificity of the classifier are 98.6% (95% confidence interval [CI] 92.7%-100%) and 98.1% (95% CI 89.9%-100%), respectively. High concentrations of MMP7 alone (>/=1.99 ng/ml) correctly classify 69 of 74 IPF patients (93.2%) but incorrectly classify five normal samples as IPF and five IPF samples as controls, whereas the combination of high plasma concentrations of both MMP7 (>/=1.99 ng/ml) and MMP1 (>/=2.15 ng/ml) excludes all controls. Thus the combination of high MMP7 and high MMP1 concentrations can distinguish IPF patients from controls. Receiver operating characteristic curves (ROCs) (Figure 1C) confirm that MMP7 is the best univariate classifier, although the combination of five markers performs somewhat better (Figure 1C), as does the combination of MMP7 and MMP1 (unpublished data).
###end p 68
###begin title 69
###xml 57 65 <span type="species:ncbi:9606">Patients</span>
MMP7 and MMP1 Are Increased in the Lung and BAL Fluid of Patients with IPF
###end title 69
###begin p 70
###xml 235 243 235 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g002">Figure 2</xref>
###xml 305 313 305 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g001">Figure 1</xref>
###xml 588 595 588 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050093-t003">Table 3</xref>
###xml 696 704 696 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g002">Figure 2</xref>
###xml 569 577 <span type="species:ncbi:9606">patients</span>
To determine whether protein concentration differences in peripheral blood reflect gene expression differences present in the lung, we analyzed gene expression patterns in 23 IPF and 14 control lungs using oligonucleotide microarrays (Figure 2A). Of the five plasma proteins in the CART plasma signature (Figure 1B), only the genes for MMP7 and MMP1 are significantly overexpressed in IPF lungs compared to controls (SAM Q value = 0 for both genes; 7.3- and 15.7-fold increase, respectively). Of the ten other proteins that are significantly different in the plasma of patients with IPF (Table 3), the genes for MMP3, AGER, and IL12B are also significantly differentially expressed in IPF lungs (Figure 2A).
###end p 70
###begin title 71
###xml 82 90 <span type="species:ncbi:9606">Patients</span>
MMP7 and MMP1 Gene and Protein Levels Are Significantly Increased in the Lungs of Patients with IPF
###end title 71
###begin p 72
###xml 148 149 148 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
(A) Average gene expression levels (log scale) measured using gene expression microarrays of genes that encode the 49 protein markers in IPF lungs (y-axis) compared to control lungs (x-axis). Colored squares (black or red) are genes that encode proteins that changed significantly in plasma. Red squares are genes that changed significantly (SAM Q value <5%) in gene expression data and that encode proteins measured in peripheral blood. Green oblique lines denote 2-fold change.
###end p 72
###begin p 73
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 90 91 90 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 157 158 157 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
(B and C) MMP7 (B) and MMP1 (C) concentrations (ng/ml) are significantly (p < 0.00001 and p = 0.018, respectively) higher in BAL fluid of patients with IPF (n = 22) compared to control individuals (n = 10).
###end p 73
###begin p 74
###xml 298 299 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 314 315 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 340 348 340 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g002">Figure 2</xref>
###xml 354 355 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g002">2</xref>
###xml 150 158 <span type="species:ncbi:9606">patients</span>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
To determine whether MMP7 and MMP1 proteins are secreted into the alveolar microenvironment, we measured their concentrations in BAL obtained from 22 patients with IPF and ten control individuals. MMP7 and MMP1 BAL concentrations are significantly higher in IPF patients when compared to controls (p < 0.00001 and p = 0.018, respectively) (Figure 2B and 2C). Hence, elevated MMP7 and MMP1 levels in the lung microenvironment are the most likely source for their increased concentrations in peripheral blood.
###end p 74
###begin title 75
###xml 35 43 <span type="species:ncbi:9606">Patients</span>
MMP7 and MMP1 Are Not Increased in Patients with COPD or Sarcoidosis
###end title 75
###begin p 76
###xml 306 307 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 362 363 362 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 383 391 383 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g003">Figure 3</xref>
###xml 464 465 464 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 475 483 475 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g003">Figure 3</xref>
###xml 495 496 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 506 514 506 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g003">Figure 3</xref>
###xml 666 667 666 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 679 680 679 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 700 701 700 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 780 781 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 799 800 799 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 867 875 867 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g003">Figure 3</xref>
###xml 881 882 881 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g003">3</xref>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
###xml 206 214 <span type="species:ncbi:9606">patients</span>
###xml 615 627 <span type="species:ncbi:9606">participants</span>
###xml 832 840 <span type="species:ncbi:9606">patients</span>
To determine whether concentrations of MMP7 and MMP1 are increased in other common chronic lung diseases, we measured plasma concentrations in patients affected with sarcoidosis or COPD. The 47 sarcoidosis patients were stratified into those with evidence for parenchymal lung disease (stage 2 or greater; n = 29) and those with no lung parenchymal involvement (n = 18). As shown in Figure 3, there are no significant differences in plasma concentrations of MMP7 (p = 0.78) (Figure 3A) or MMP1 (p = 0.27) (Figure 3B) between the sarcoidosis groups with or without lung abnormalities when compared to controls. COPD participants were grouped by GOLD class, into 0-I (n = 13), II (n = 21), and III-IV (n = 39). No significant differences are found in plasma concentrations of MMP7 (p = 0.21) or MMP1 (p = 0.85) between groups of COPD patients stratified by GOLD class (Figure 3A and 3B, respectively).
###end p 76
###begin title 77
MMP7 and MMP1 Plasma Concentrations Are High in IPF, but Not Sarcoidosis or COPD
###end title 77
###begin p 78
###xml 95 96 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 103 104 103 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 119 120 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 167 168 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 205 206 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 218 219 218 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 265 266 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 282 283 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 290 291 290 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Concentrations (ng/ml) of MMP7 (A) and MMP1 (B) are significantly higher in patients with IPF (n = 74; p < 0.00001 and p = 0.018, respectively), compared to controls (n = 53), but not sarcoidosis (n = 47; p = 0.78 and p = 0.28, respectively), compared to controls (n = 53) or COPD (n = 73; p = 0.21 and 0.85, respectively, stratified by GOLD class, as 0-I, II, and III-IV).
###end p 78
###begin title 79
###xml 55 63 <span type="species:ncbi:9606">Patients</span>
###xml 85 93 <span type="species:ncbi:9606">Patients</span>
MMP7 and MMP1 Are Significantly Higher in the Serum of Patients with IPF Compared to Patients with HP
###end title 79
###begin p 80
###xml 236 237 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 256 257 256 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 378 386 378 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g004">Figure 4</xref>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g004">4</xref>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
To determine whether peripheral blood concentrations of MMP7 and MMP1 distinguish IPF from other common forms of ILD, we measured their levels in 41 patients with HP and 34 patients with IPF. Univariately, serum concentrations of MMP7 (p = 0.01) and MMP1 (p < 0.001) are significantly higher in IPF compared to HP; fold changes for MMP1 and MMP7 are 2.3 and 1.31, respectively (Figure 4A and 4B).
###end p 80
###begin title 81
MMP7 and MMP1 Serum Concentrations Are Higher in IPF, Compared to HP
###end title 81
###begin p 82
###xml 118 119 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 152 153 152 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
(A and B) Concentrations (ng/ml) of MMP7 (A) and MMP1 (B) in the blood are significantly higher in patients with IPF (n = 34) than in patients with HP (n = 41).
###end p 82
###begin p 83
###xml 63 64 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 87 88 87 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
(C) Average gene expression levels (log scale) in IPF samples (y-axis) compared to HP (x-axis) measured by gene expression microarrays. Gray circles, all genes on the array; red circles, MMP1 and MMP7. Green oblique lines denote 2-fold change.
###end p 83
###begin p 84
###xml 32 33 32 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 65 66 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 212 215 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
(D) Combinations of serum MMP7 (y-axis) and MMP1 concentrations (x-axis) in IPF (closed circles) and HP patients (open circles). Corners represent points in which the trade-off between positive predictive value (PPV) and negative predictive value (NPV) are optimal for ruling out IPF (blue) or concluding IPF (red) on the basis of MMP1 and MMP7 concentrations.
###end p 84
###begin p 85
###xml 149 150 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 209 210 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
(E) ROC curves for using MMP1 or MMP7, or their combination, to classify samples as IPF or HP. Sensitivity, or true positive rate, is plotted on the y-axis, and false positive rate, or 1 - specificity, on the x-axis. The identity line at 45 degrees represents a marker that performed no better than classifying samples as IPF or HP by flipping a fair coin.
###end p 85
###begin p 86
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b018">18</xref>
###xml 421 429 421 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g004">Figure 4</xref>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
Similar results are observed in a reanalysis of a previously published DNA microarray dataset comparing gene expression in lung tissue obtained from IPF and HP patients [18]. In this reanalysis, MMP7 and MMP1 levels are significantly higher in IPF compared to HP (false discovery rate [FDR] < 5%), however, as observed in the peripheral blood, the change in MMP7 levels is moderate when compared to the increase in MMP1 (Figure 4C).
###end p 86
###begin p 87
###xml 298 306 298 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g004">Figure 4</xref>
###xml 510 518 510 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g004">Figure 4</xref>
###xml 106 113 <span type="species:ncbi:9606">patient</span>
Combinations of serum MMP1 and MMP7 concentrations have positive predictive values for determining that a patient has IPF ranging from 91% (MMP7 > 2.6 ng/ml and MMP1 > 8.9 ng/ml) to 66%, and negative predictive value (ruling out IPF) ranging from 96% (MMP7 < 2.9 ng/ml and MMP1 > 3.5ng/ml) to 70% (Figure 4D). Additionally, the combination of high MMP7 and high MMP1 peripheral blood concentrations distinguish IPF from HP with 96.3% sensitivity (95% CI 81.0%-100%) and 87.2% specificity (95% CI 72.6%-95.7%) (Figure 4E), further supporting that MMP1 in combination with MMP7 distinguishes IPF from HP.
###end p 87
###begin title 88
MMP7 and MMP1 Are Significantly Higher in the Serum of an Independent Validation Cohort
###end title 88
###begin p 89
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b021">21</xref>
###xml 464 465 464 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 478 479 478 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 629 630 629 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 706 707 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 719 727 719 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g005">Figure 5</xref>
###xml 953 955 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b030">30</xref>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 409 417 <span type="species:ncbi:9606">patients</span>
###xml 541 549 <span type="species:ncbi:9606">patients</span>
###xml 676 684 <span type="species:ncbi:9606">patients</span>
###xml 868 876 <span type="species:ncbi:9606">patients</span>
To verify our findings, we measured serum concentrations of MMP7 and MMP1 in an independent validation cohort comprised of patients affected with IPF, familial pulmonary fibrosis, or subclinical ILD, and control individuals. This cohort has been recently described by us [21]. Even though concentrations were measured in serum and not plasma, significantly higher concentrations of MMP7 and MMP1 are found in patients with pulmonary fibrosis compared to controls (p < 0.001 and p = 0.01, respectively). Notably, serum MMP7 concentrations in patients with subclinical ILD are significantly higher compared to control individuals (p = 0.019) and significantly lower compared to patients with full-blown IPF (p < 0.0001) (Figure 5A), suggesting that MMP7 may serve as a biomarker for disease progression. There is no significant difference in MMP7 concentrations between patients with familial or sporadic IPF, consistent with the findings of Yang et al. [30].
###end p 89
###begin title 90
MMP7 Concentrations Significantly Distinguish Control from Subclinical ILD, Familial, or Sporadic IPF
###end title 90
###begin p 91
(A) Dark solid lines show median concentrations in each group. The interquartile range (IR) or middle 50% of concentrations is delimited by a box. Data are expressed on a log base 2 scale.
###end p 91
###begin p 92
(B) ROC curves for using MMP1 or MMP7, or their combination, to classify samples as IPF (sporadic or familial) or control in validation cohort.
###end p 92
###begin p 93
###xml 90 92 90 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CO</sub>
###xml 193 194 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 205 206 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(C and D) Serum MMP7 concentrations moderately correlate with decreases in FVC% (C) and DLCO% (D). Linear regressions and 95% CI inversely relate MMP7 concentration (ng/ml) to FVC% and DLCO%. *p < 0.05, **p < 0.01, and ***p < 0.001.
###end p 93
###begin p 94
###xml 259 267 259 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g005">Figure 5</xref>
In this cohort, elevated MMP1 concentrations combined with high concentrations of MMP7 can distinguish IPF from controls with 89.2% sensitivity (95% CI 71.8%-91.7%) and 95.0% specificity (95% CI 75.1%-99.9%), supporting the findings in our derivation cohort (Figure 5B).
###end p 94
###begin title 95
MMP7 Concentrations Correlate Moderately with Disease Severity
###end title 95
###begin p 96
###xml 310 318 310 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g005">Figure 5</xref>
###xml 327 329 327 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CO</sub>
###xml 332 340 332 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050093-g005">Figure 5</xref>
###xml 389 391 389 391 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CO</sub>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 405 406 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 434 435 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 445 446 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
To determine whether concentrations of MMP7 or MMP1 correlate with disease severity, we compared pulmonary function measurements with serum concentrations of MMP7 and MMP1 in the validation cohort. We found a significant correlation between higher MMP7 concentrations and disease severity as measured by FVC% (Figure 5C) and DLCO% (Figure 5D). Fitted models predict a decline of 4.1% in DLCO% (p = 0.002, r = -0.53) and 4.0% in FVC% (p = 0.002, r = -0.51) for each increment of 1 ng/ml in serum MMP7. We did not find any statistically significant correlation between MMP1 concentrations and pulmonary function measurements (unpublished data).
###end p 96
###begin title 97
Discussion
###end title 97
###begin p 98
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b031">31</xref>
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b032">32</xref>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b034">34</xref>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 304 312 <span type="species:ncbi:9606">patients</span>
###xml 550 558 <span type="species:ncbi:9606">patients</span>
###xml 761 769 <span type="species:ncbi:9606">patients</span>
Overall, our study demonstrates the first evidence for a peripheral blood protein signature in IPF patients to our knowledge. MMP7 and MMP1, two matrix metalloproteases previously implicated in the pathogenesis of IPF [31], are significantly increased in plasma, serum, BAL fluid, and lung tissue of IPF patients, suggesting that increased MMP7 and MMP1 levels in the peripheral blood are indicative of the pathologic changes that characterize the IPF alveolar microenvironment. Used in combination, blood levels of MMP1 and MMP7 can distinguish IPF patients from diverse types of chronic lung disease including HP, a common interstitial pneumonia that can sometimes be indistinguishable from IPF [32-34]. Increases in MMP7 blood concentrations are observed in patients with subclinical familial pulmonary fibrosis, and higher levels of MMP7 are associated with disease severity. Taken together our findings support the use of MMP1 and MMP7 as IPF biomarkers and suggest that their role in diagnosis, early detection, and monitoring of disease progression should be further investigated.
###end p 98
###begin p 99
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b035">35</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b031">31</xref>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b036">36</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b040">40</xref>
###xml 837 839 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b039">39</xref>
###xml 924 926 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b041">41</xref>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b042">42</xref>
###xml 996 998 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b039">39</xref>
###xml 999 1001 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b043">43</xref>
###xml 1094 1096 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b039">39</xref>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 1031 1035 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Multiple MMPs are among the 12 proteins significantly increased in the blood of IPF patients. The roles of MMPs have been intensively studied and debated in IPF [35]. While multiple and often contrasting roles have been proposed for MMPs in regulating abnormal epithelial response to injury, fibroblast proliferation, extracellular matrix accumulation, and aberrant tissue remodeling, the consensus is that this family of matrix degrading enzymes is involved in disease pathogenesis [31,36-40]. The two top-ranked proteins in this study are MMPs known to be significantly overexpressed in the activated alveolar epithelium in IPF lungs. MMP1, a matrix metalloprotease that primarily degrades fibrillar collagen, is rarely expressed under normal conditions, but is highly overexpressed in reactive alveolar epithelial cells in IPF lungs [39]. MMP7, a matrix metalloprotease with multiple local inflammatory regulatory roles [41,42], is also highly upregulated in alveolar epithelial cells in IPF [39,43]. Furthermore, MMP7 knockout mice are relatively protected from bleomycin-induced fibrosis [39], suggesting that MMP7 may have a profibrotic effect in IPF. Taken in the above context, our results strongly suggest that activated epithelial cells in IPF lungs are the likely source of elevated peripheral blood concentrations of MMP1 and MMP7, thus supporting their use as biomarkers for disease detection and progression.
###end p 99
###begin p 100
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b032">32</xref>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b034">34</xref>
###xml 1132 1134 1132 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b033">33</xref>
###xml 1135 1137 1135 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b034">34</xref>
###xml 1138 1140 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b044">44</xref>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
Our data show that neither patients with COPD, a chronic progressive lung disease, nor patients with sarcoidosis, a chronic granulomatous ILD, express significantly increased peripheral blood concentrations of MMP7 or MMP1. Further, elevated peripheral blood MMP1 concentrations, in the presence of elevated MMP7 concentrations, distinguish IPF from HP. A similar trend in gene expression of MMP7 and MMP1 is found in the lungs of patients with IPF and HP, further supporting the notion that the changes in peripheral blood concentrations of MMP7 and MMP1 are reflective of the lung gene environment and constitute a disease-specific signal. This finding may be very important clinically, because subacute HP is frequently misdiagnosed as idiopathic nonspecific interstitial pneumonia (NSIP), and in its chronic advanced form HP can be undistinguishable from IPF [32-34]. In fact, recent studies have demonstrated that histopathologic and HRCT abnormalities observed in chronic HP often overlap with those of usual interstitial pneumonia (UIP), representing an important challenge to the differential diagnosis of these conditions [33,34,44]. Thus, the elevated peripheral blood concentrations of MMP7 and MMP1 observed in IPF are not due to a systemic stress response to a chronic lung disease and distinguish COPD, sarcoidosis, and HP from IPF. While we do not advocate at this stage relying solely on peripheral blood concentrations of MMP7 and MMP1 in distinguishing IPF from HP, sarcoidosis, or the less difficult differential diagnosis of COPD, it seems likely that knowing these concentrations will impact clinical decision-making.
###end p 100
###begin p 101
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b030">30</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b045">45</xref>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b046">46</xref>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 530 538 <span type="species:ncbi:9606">patients</span>
###xml 808 816 <span type="species:ncbi:9606">patients</span>
We did not compare IPF to other idiopathic interstitial pneumonias such as NSIP. There is nothing in our data to suggest that we can distinguish IPF from these diseases using MMP7 and MMP1 peripheral blood concentrations. In fact the finding of elevated MMP7 in patients with subclinical ILD may be indicative that this increase may be present in other idiopathic ILDs. Furthermore, gene expression patterns were found to be extremely similar in IPF and NSIP [30,45], and BAL MMP7 levels were also recently found to be similar in patients with IPF and NSIP [46]. The major limitation in these studies was the small number of cases with NSIP because of the substantial rarity of isolated NSIP. Therefore our results should encourage the establishment of multicenter collections of peripheral blood samples of patients with ILD with sufficient power to determine whether NSIP and IPF differ in their peripheral blood protein expression.
###end p 101
###begin p 102
###xml 828 830 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b019">19</xref>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b021">21</xref>
###xml 1267 1269 1267 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050093-b031">31</xref>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 594 602 <span type="species:ncbi:9606">patients</span>
###xml 671 679 <span type="species:ncbi:9606">patients</span>
###xml 952 960 <span type="species:ncbi:9606">patients</span>
In comparison to other studies, major attributes of our analysis include the relatively large size of our derivation cohort and the large number of proteins assayed in this cohort of patients with IPF, the comparison of peripheral blood biomarker levels with their gene expression levels in the lungs and BAL, the comparison with multiple relatively large control populations with other chronic lung diseases to establish specificity of our findings, and the verification of our initial results in an independent validation cohort. A unique feature of our validation cohort is that it contains patients with subclinical ILD who are asymptomatic first-degree relatives of patients affected with familial IPF. These individuals have HRCT findings of early ILD, but do not have pulmonary function abnormalities, cough, or dyspnea [19,21]. Analysis of samples from this cohort allowed us to demonstrate that MMP7 concentrations are significantly higher in patients with early subclinical lung disease, suggesting that MMP7 may be a marker for early asymptomatic ILD. Peripheral blood concentrations of MMP7 also correlate with pulmonary function tests, which are surrogate measures of disease severity and thus may reflect molecular mechanisms of lung remodeling in IPF [31]. Naturally, the use of different platforms and different sample types limits our ability at this stage to set a disease-specific MMP concentration threshold. However, the reproducibility and concordance of our results across different sample types and in multiple cohorts suggest that such a threshold can and should be determined.
###end p 102
###begin p 103
###xml 542 550 <span type="species:ncbi:9606">patients</span>
###xml 956 964 <span type="species:ncbi:9606">patients</span>
In conclusion, in this study we report for the first time to our knowledge the presence of a peripheral blood protein signature in a disease that is confined to the lung. This signature is composed of MMPs, TNF receptors, and some chemokines. Our data demonstrate that peripheral blood increases in two of these markers (MMP1 and MMP7) are also observed in lung and may be specific to IPF. We provide verification of our observations in an independent validation cohort and show that MMP7 correlates with disease severity and is increased in patients with subclinical ILD. While additional studies will determine the value of this protein signature in clinical practice, our results support a potential value of peripheral blood proteins as biomarkers in an organ-confined disease such as IPF. If validated, these biomarkers have the potential to greatly facilitate the introduction of new therapies in IPF and to profoundly affect the management of these patients.
###end p 103
###begin title 104
Supporting Information
###end title 104
###begin title 105
Russian Translation of the Abstract by Anna E. Lokshin
###end title 105
###begin p 106
(24 KB DOC)
###end p 106
###begin p 107
Click here for additional data file.
###end p 107
###begin title 108
Spanish Translation of the Abstract by Moises Selman
###end title 108
###begin p 109
(42 KB DOC)
###end p 109
###begin p 110
Click here for additional data file.
###end p 110
###begin title 111
Japanese Translation of the Abstract by Kazuhisa Konishi
###end title 111
###begin p 112
(22 KB DOC)
###end p 112
###begin p 113
Click here for additional data file.
###end p 113
###begin title 114
Chinese Translation of the Abstract
###end title 114
###begin p 115
(38 KB DOC)
###end p 115
###begin p 116
Click here for additional data file.
###end p 116
###begin title 117
Hebrew Translation of the Abstract
###end title 117
###begin p 118
(69 KB DOC)
###end p 118
###begin p 119
Click here for additional data file.
###end p 119
###begin title 120
Supplementary Methods
###end title 120
###begin p 121
(148 KB DOC)
###end p 121
###begin p 122
Click here for additional data file.
###end p 122
###begin title 123
Accession Numbers
###end title 123
###begin p 124
The Entrez Gene IDs () of the proteins discussed in this paper are: AGER, 177; CCL11, 6356; CXCL10, 3627; IL12B, 3593; IGFBP1, 3484; MMP1, 4312; MMP3, 4314; MMP7, 4316; MMP8, 4317; MMP9, 5318; TNFRSF1A, 7132; TNFRSF1B, 7133.
###end p 124
###begin p 125
###xml 329 337 <span type="species:ncbi:9606">patients</span>
The authors wish to thank L. Chensny, A. Marrangoni, K. Johnson, and M. Bisceglia for their help in processing the samples and D. Plaskon for maintaining the database. A. Choi, J. Moss, E. Feingold, and J. Lee provided useful discussions and suggestions. This research would not have been possible without the cooperation of the patients of the Simmons Center and the Pulmonary-Critical Care Medicine Branch.
###end p 125
###begin title 126
Abbreviations
###end title 126
###begin p 127
bronchoalveolar lavage
###end p 127
###begin p 128
classification and regression tree
###end p 128
###begin p 129
confidence interval
###end p 129
###begin p 130
chronic obstructive pulmonary disease
###end p 130
###begin p 131
percent predicted carbon monoxide diffusing capacity
###end p 131
###begin p 132
percent predicted forced vital capacity
###end p 132
###begin p 133
hypersensitivity pneumonitis
###end p 133
###begin p 134
high-resolution computed tomography
###end p 134
###begin p 135
interstitial lung disease
###end p 135
###begin p 136
idiopathic pulmonary fibrosis
###end p 136
###begin p 137
matrix metalloprotease
###end p 137
###begin p 138
nonspecific interstitial pneumonia
###end p 138
###begin p 139
receiver operating characteristic curve
###end p 139
###begin p 140
significance analysis of microarrays
###end p 140
###begin title 141
References
###end title 141
###begin article-title 142
Classification and natural history of the idiopathic interstitial pneumonias
###end article-title 142
###begin article-title 143
Gene expression profiling as a window into idiopathic pulmonary fibrosis pathogenesis: can we identify the right target genes
###end article-title 143
###begin article-title 144
###xml 64 72 <span type="species:ncbi:99490|species:ncbi:9783|species:ncbi:9785">elephant</span>
The mechanisms of idiopathic pulmonary fibrosis: can we see the elephant
###end article-title 144
###begin article-title 145
Mechanisms and mediators of pulmonary fibrosis
###end article-title 145
###begin article-title 146
Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis
###end article-title 146
###begin article-title 147
Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis
###end article-title 147
###begin article-title 148
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases
###end article-title 148
###begin article-title 149
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases
###end article-title 149
###begin article-title 150
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis
###end article-title 150
###begin article-title 151
###xml 45 53 <span type="species:ncbi:9606">patients</span>
High plasma concentrations of osteopontin in patients with interstitial pneumonia
###end article-title 151
###begin article-title 152
Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)
###end article-title 152
###begin article-title 153
Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification
###end article-title 153
###begin article-title 154
Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model
###end article-title 154
###begin article-title 155
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary
###end article-title 155
###begin article-title 156
ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders
###end article-title 156
###begin article-title 157
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999
###end article-title 157
###begin article-title 158
Local and circulating microchimerism is associated with hypersensitivity pneumonitis
###end article-title 158
###begin article-title 159
Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis
###end article-title 159
###begin article-title 160
Clinical and pathologic features of familial interstitial pneumonia
###end article-title 160
###begin article-title 161
Impairment of alveolar macrophage transcription in idiopathic pulmonary fibrosis
###end article-title 161
###begin article-title 162
Early interstitial lung disease in familial pulmonary fibrosis
###end article-title 162
###begin article-title 163
###xml 53 58 <span type="species:ncbi:9606">human</span>
Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis
###end article-title 163
###begin article-title 164
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001
###end article-title 164
###begin article-title 165
Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern
###end article-title 165
###begin article-title 166
Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer
###end article-title 166
###begin article-title 167
Comparison of normalization methods for CodeLink Bioarray data
###end article-title 167
###begin article-title 168
Significance analysis of microarrays applied to the ionizing radiation response
###end article-title 168
###begin article-title 169
R: A language for data analysis and graphics
###end article-title 169
###begin article-title 170
A functional and regulatory map of asthma
###end article-title 170
###begin article-title 171
Gene expression profiling of familial and sporadic interstitial pneumonia
###end article-title 171
###begin article-title 172
Matrix metalloproteases in aberrant fibrotic tissue remodeling
###end article-title 172
###begin article-title 173
###xml 21 29 <span type="species:ncbi:9606">patients</span>
Mortality in Mexican patients with chronic pigeon breeder's lung compared with those with usual interstitial pneumonia
###end article-title 173
###begin article-title 174
Chronic bird fancier's lung: histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias
###end article-title 174
###begin article-title 175
Chronic hypersensitivity pneumonitis
###end article-title 175
###begin article-title 176
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Collagenase in the lower respiratory tract of patients with idiopathic pulmonary fibrosis
###end article-title 176
###begin article-title 177
Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias
###end article-title 177
###begin article-title 178
TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment
###end article-title 178
###begin article-title 179
Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases
###end article-title 179
###begin article-title 180
###xml 88 92 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 97 103 <span type="species:ncbi:9606">humans</span>
Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans
###end article-title 180
###begin article-title 181
Approaching the degradome in idiopathic pulmonary fibrosis
###end article-title 181
###begin article-title 182
Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury
###end article-title 182
###begin article-title 183
Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium
###end article-title 183
###begin article-title 184
Overexpression of matrix metalloproteinase-7 in pulmonary fibrosis
###end article-title 184
###begin article-title 185
Hypersensitivity pneumonitis: spectrum of high-resolution CT and pathologic findings
###end article-title 185
###begin article-title 186
When it comes to genes-IPF or NSIP, familial or sporadic-they're all the same
###end article-title 186
###begin article-title 187
Elevated matrilysin levels in bronchoalveolar lavage fluid do not distinguish idiopathic pulmonary fibrosis from other interstitial lung diseases
###end article-title 187
###begin p 188
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 553 564 <span type="species:ncbi:9606">participant</span>
###xml 847 858 <span type="species:ncbi:9606">participant</span>
###xml 993 1004 <span type="species:ncbi:9606">participant</span>
###xml 1139 1150 <span type="species:ncbi:9606">participant</span>
###xml 1345 1356 <span type="species:ncbi:9606">participant</span>
###xml 1635 1646 <span type="species:ncbi:9606">participant</span>
###xml 1702 1709 <span type="species:ncbi:9606">patient</span>
###xml 1872 1883 <span type="species:ncbi:9606">participant</span>
Author contributions. IOR contributed to recruitment and analysis of the validation cohort, data analysis, conceptualization and design of the study, data analysis, and manuscript preparation. TJR contributed to project conceptualization, data analysis, statistics, and writing of the initial draft of the paper. KK contributed to microarray data generation and analysis, conceptualization of the study, and manuscript generation. YZ contributed to sample collection and protocol development, data analysis, and manuscript generation. KG contributed to participant recruitment, diagnosis, and ascertainment of the sarcoidosis cohort as well as the derivation cohort, protocol development, planning of experiments, and manuscript preparation. AEL contributed to Luminex data generation including custom assays and data analysis. KOL contributed to participant recruitment and diagnosis ascertainment of the derivation cohort, protocol development, and manuscript preparation. JC contributed to participant recruitment and diagnosis ascertainment of the HP cohort, ELISA assays, data analysis, and manuscript preparation. SDM contributed to participant recruitment and diagnosis ascertainment of the validation cohort, protocol development, and manuscript preparation. AP contributed to data analysis and manuscript preparation. FS contributed to participant recruitment and diagnosis ascertainment of the COPD cohort, protocol development, and manuscript preparation. JD contributed to conceptualization of proposed studies, diagnosis ascertainment of the derivation cohort, data analysis, and manuscript preparation. MS contributed to participant recruitment and diagnosis ascertainment of all Mexican patient cohorts, planning of the study, preparation of early drafts, and manuscript development. BRG contributed to design and conceptualization of the research project, participant recruitment and diagnosis ascertainment of the validation cohort, protocol development, and manuscript preparation. NK contributed to design and conceptualization of the research project, analysis of all data including gene expression and protein measurements, paper writing, and manuscript submission.
###end p 188
###begin p 189
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: NK, KG, TJR, YZ, JD, KOL, and MS were supported by National Institute of Health (NIH) grants HL073745, HL0793941, HL0894932, and a generous donation from the Simmons family. IOR, SDM, and BRG were supported by the Division of Intramural Research of the National Heart, Lung, and Blood Institute (NHLBI). MS and AP were supported by Universidad Nacional Autonoma de Mexico Grant SDI.PTID.05.6. The funding institutions have not been involved in study design, data collection, interpretation, or preparation of this manuscript.
###end p 189
###begin p 190
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: NK is a recipient of investigator initiated research grants from Biogen Idec and from Centocor for genomic and proteomic biomarker discovery and validation. Data presented in this paper were not funded by any of these grants. FS, as a consultant, has received less than $10,000 from GlaxoSmithKline (GSK) and Astra-Zeneca. All other authors declared no competing interests.
###end p 190

